Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2011-P-000217 | Other Identifier | Partners Human Research Committee |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Sanofi | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this study is to design and implement an intensive discharge intervention for inpatients with type 2 diabetes and cardiovascular disease, and determine the effects of the intervention on post-discharge insulin adherence, glycemic control, cardiac medication adherence, hypoglycemic events, and emergency department visits and hospital readmissions.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intensive discharge intervention | Experimental | The intervention is a multi-modal program consisting of the following:
|
|
| Usual Care | No Intervention | Patients in the control arm of this study receive usual care. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intensive discharge intervention | Other | The intervention is a multi-modal program consisting of the following:
|
| Measure | Description | Time Frame |
|---|---|---|
| Cardiac medication adherence | Cardiac medication adherence as determined by patient self report 30 days after discharge | 30 days after discharge |
| Measure | Description | Time Frame |
|---|---|---|
| Glycemic control | Glycemic control as determined by change in A1c 90 days after discharge. | 90 days after discharge |
| Emergency department visits | Emergency department visits within 30 days of discharge. |
Not provided
Inclusion Criteria:
Adult inpatients at BWH on the medicine or cardiology services with a primary care physician who belongs to a participating practice or has not explicitly opted out of the study
Type 2 diabetes
Active cardiovascular disease
Likely to be discharged home, and one of the following:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jeffrey L Schnipper, MD, MPH, FHM | Brigham and Women's Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | United States |
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D002318 | Cardiovascular Diseases |
| D055118 | Medication Adherence |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Within 30 days after discharge |
| Number of self-reported hypoglycemic events | Number of self-reported hypoglycemic events within 30 days of discharge. | Within 30 days of discharge |
| Number of patient-days with hypoglycemia | Number of patient-days with hypoglycemia (point-of-care glucose less than 70 mg/dL) or with severe hypoglycemia (less than 40 mg/dL) within 30 days of discharge | Within 30 days of discharge |
| Cardiac medication adherence | Cardiac medication adherence as determined by pharmacy refill rates for 90 days after discharge. | 90 days after discharge |
| Hospital Readmissions | Hospital readmissions within 30 days of discharge. | Within 30 days of discharge |
| D004700 | Endocrine System Diseases |
| D010349 | Patient Compliance |
| D010342 | Patient Acceptance of Health Care |
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
| D001519 | Behavior |